# US 2021/0332145 A1 · Anti-bcma antibodies > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0332145 A1 - Document ID: US20210332145A1 - Status: Published application - Kind: A1 - Application number: 17/284,371 - Filed: 2019-10-09 - Published: 2021-10-28 - Earliest claimed: 2018-10-09 - Assignees: Single Cell Technology, Inc.; ACROBiosystems, Inc. - Applicants: Single Cell Technology, Inc.; ACROBiosystems, Inc. - Inventors: Leyan TANG; Allison SCHULKINS; Kimberly THAN; Chun-Nan CHEN; Jingyun MIAO; Xiaohui ZHANG; Xiaojuan SHI; Lin ZHANG - Web page: https://patentgrep.com/patent/US20210332145A1 ## CPC - C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95} - A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum - A61K 47/6851: {the antibody targeting a determinant of a tumour cell} - A61P 35/00: Antineoplastic agents - G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC] - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Provided are antibodies that recognize the B-Cell Maturation Antigen (BCMA) and methods of use thereof. ## Claims ### Claim 1 An antibody that binds human BCMA (SEQ ID NO:1) comprising: a) a HCDR1 having the amino acid sequence of SEQ ID NO:50, a HCDR2 having the amino acid sequence of SEQ ID NO:76, a HCDR3 having the amino acid sequence of SEQ ID NO:94, a LCDR1 having the amino acid sequence of SEQ ID NO:61, a LCDR2 having the amino acid sequence of SEQ ID NO:85, and a LCDR3 having the amino acid sequence of SEQ ID NO:105; or b) a HCDR1 having the amino acid sequence of SEQ ID NO:50, a HCDR2 having the amino acid sequence of SEQ ID NO:76, a HCDR3 having the amino acid sequence of SEQ ID NO:95, a LCDR1 having the amino acid sequence of SEQ ID NO:61, a LCDR2 having the amino acid sequence of SEQ ID NO:85, and a LCDR3 having the amino acid sequence of SEQ ID NO:106; or c) a HCDR1 having the amino acid sequence of SEQ ID NO:50, a HCDR2 having the amino acid sequence of SEQ ID NO:76, a HCDR3 having the amino acid sequence of SEQ ID NO:96, a LCDR1 having the amino acid sequence of SEQ ID NO:61, a LCDR2 having the amino acid sequence of SEQ ID NO:85, and a LCDR3 having the amino acid sequence of SEQ ID NO:107; or d) a HCDR1 having the amino acid sequence of SEQ ID NO:50, a HCDR2 having the amino acid sequence of SEQ ID NO:76, a HCDR3 having the amino acid sequence of SEQ ID NO:97, a LCDR1 having the amino acid sequence of SEQ ID NO:61, a LCDR2 having the amino acid sequence of SEQ ID NO:85, and a LCDR3 having the amino acid sequence of SEQ ID NO:107; or e) a HCDR1 having the amino acid sequence of SEQ ID NO:46, a HCDR2 having the amino acid sequence of SEQ ID NO:72, a HCDR3 having the amino acid sequence of SEQ ID NO:90, a LCDR1 having the amino acid sequence of SEQ ID NO:57, a LCDR2 having the amino acid sequence of SEQ ID NO:82, and a LCDR3 having the amino acid sequence of SEQ ID NO:101; or f) a HCDR1 having the amino acid sequence of SEQ ID NO:48, a HCDR2 having the amino acid sequence of SEQ ID NO:74, a HCDR3 having the amino acid sequence of SEQ ID NO:92, a LCDR1 having the amino acid sequence of SEQ ID NO:59, a LCDR2 having the amino acid sequence of SEQ ID NO:84, and a LCDR3 having the amino acid sequence of SEQ ID NO:103. ### Claim 2 (depends on 1) The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:50, the HCDR2 has the amino acid sequence of SEQ ID NO:76, the HCDR3 has the amino acid sequence of SEQ ID NO:94, the LCDR1 has the amino acid sequence of SEQ ID NO:61, the LCDR2 has the amino acid sequence of SEQ ID NO:85, and the LCDR3 has the amino acid sequence of SEQ ID NO:105. ### Claim 3 (depends on 1) The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:50, the HCDR2 has the amino acid sequence of SEQ ID NO:76, the HCDR3 has the amino acid sequence of SEQ ID NO:95, the LCDR1 has the amino acid sequence of SEQ ID NO:61, the LCDR2 has the amino acid sequence of SEQ ID NO:85, and the LCDR3 has the amino acid sequence of SEQ ID NO:106. ### Claim 4 (depends on 1) The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:50, the HCDR2 has the amino acid sequence of SEQ ID NO:76, the HCDR3 has the amino acid sequence of SEQ ID NO:96, the LCDR1 has the amino acid sequence of SEQ ID NO:61, the LCDR2 has the amino acid sequence of SEQ ID NO:85, and the LCDR3 has the amino acid sequence of SEQ ID NO:107. ### Claim 5 (depends on 1) The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:50, the HCDR2 has the amino acid sequence of SEQ ID NO:76, the HCDR3 has the amino acid sequence of SEQ ID NO:97, the LCDR1 has the amino acid sequence of SEQ ID NO:61, the LCDR2 has the amino acid sequence of SEQ ID NO:85, and the LCDR3 has the amino acid sequence of SEQ ID NO:107. ### Claim 6 (depends on 1) The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:46, the HCDR2 has the amino acid sequence of SEQ ID NO:72, the HCDR3 has the amino acid sequence of SEQ ID NO:90, the LCDR1 has the amino acid sequence of SEQ ID NO:57, the LCDR2 has the amino acid sequence of SEQ ID NO:82, and the LCDR3 has the amino acid sequence of SEQ ID NO:101. ### Claim 7 (depends on 1) The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:48, the HCDR2 has the amino acid sequence of SEQ ID NO:74, the HCDR3 has the amino acid sequence of SEQ ID NO:92, the LCDR1 has the amino acid sequence of SEQ ID NO:59, the LCDR2 has the amino acid sequence of SEQ ID NO:84, and the LCDR3 has the amino acid sequence of SEQ ID NO:103. ### Claim 8 An antibody that binds human BCMA (SEQ ID NO:1) comprising: a) a VH having the amino acid sequence of SEQ ID NO:6, and a VL having the amino acid sequence of SEQ ID NO:7; or b) a VH having the amino acid sequence of SEQ ID NO:8, and a VL having the amino acid sequence of SEQ ID NO:9; or c) a VH having the amino acid sequence of SEQ ID NO:10, and a VL having the amino acid sequence of SEQ ID NO:11; or d) a VH having the amino acid sequence of SEQ ID NO:12, and a VL having the amino acid sequence of SEQ ID NO:13; or e) a VH having the amino acid sequence of SEQ ID NO:33, and a VL having the amino acid sequence of SEQ ID NO:34; or f) a VH having the amino acid sequence of SEQ ID NO:37, and a VL having the amino acid sequence of SEQ ID NO:38. ### Claim 9 (depends on 8) The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:6, and the VL has the amino acid sequence of SEQ ID NO:7. ### Claim 10 (depends on 8) The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:8, and the VL has the amino acid sequence of SEQ ID NO:9. ### Claim 11 (depends on 8) The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:10, and the VL has the amino acid sequence of SEQ ID NO:11. ### Claim 12 (depends on 8) The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:12, and the VL has the amino acid sequence of SEQ ID NO:13. ### Claim 13 (depends on 8) The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:33, and the VL has the amino acid sequence of SEQ ID NO:34. ### Claim 14 (depends on 8) The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:37, and the VL has the amino acid sequence of SEQ ID NO:38. ### Claim 15 An antibody that binds human BCMA (SEQ ID NO:1) comprising: a) a heavy-chain comprising the amino acid sequence of SEQ ID NO:6 and a light-chain comprising the amino acid sequence of SEQ ID NO:7; or b) a heavy-chain comprising the amino acid sequence of SEQ ID NO:8 and a light-chain comprising the amino acid sequence of SEQ ID NO:9; or c) a heavy-chain comprising the amino acid sequence of SEQ ID NO:10 and a light-chain comprising the amino acid sequence of SEQ ID NO:11; or d) a heavy-chain comprising the amino acid sequence of SEQ ID NO:12 and a light-chain comprising the amino acid sequence of SEQ ID NO:13; or e) a heavy-chain comprising the amino acid sequence of SEQ ID NO:33 and a light-chain comprising the amino acid sequence of SEQ ID NO:34; or f) a heavy-chain comprising the amino acid sequence of SEQ ID NO:37 and a light-chain comprising the amino acid sequence of SEQ ID NO:38. ### Claim 16 (depends on 15) The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:6 and the light-chain comprises the amino acid sequence of SEQ ID NO:7. ### Claim 17 (depends on 15) The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:8 and the light-chain comprises the amino acid sequence of SEQ ID NO:9. ### Claim 18 (depends on 15) The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:10 and the light-chain comprises the amino acid sequence of SEQ ID NO:11. ### Claim 19 (depends on 15) The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:12 and the light-chain comprises the amino acid sequence of SEQ ID NO:13. ### Claim 20 (depends on 15) The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:33 and the light-chain comprises the amino acid sequence of SEQ ID NO:34. ### Claim 21 (depends on 15) The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:37 and the light-chain comprises the amino acid sequence of SEQ ID NO:38. ### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21) A pharmaceutical composition comprising an antibody of any of claims 1-21. ### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22) A kit comprising an antibody of any of claims 1-22. ### Claim 24 (depends on 22) A method of treating a BCMA-related cancer comprising administering to a subject in need thereof a therapeutically-effective amount of an antibody of claim 22. ### Claim 25 (depends on 22) A method of targeting a chemotherapeutic or radiotherapeutic to a BCMA-expressing cancer cell comprising administering to a subject in need thereof a therapeutically-effective amount of an antibody of claim 22 conjugated to the chemotherapeutic or radiotherapeutic. ### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22) A method of detecting BCMA in vitro comprising incubating an antibody of any of claims 1-22 with a sample comprising BCMA, or an antigen thereof.